Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Biotechnology word cloud

Stifel Says Strong Earnings Will Reignite Biotech Rally

When the biotech sell-off started in late February, the stocks had been market leaders for almost four years. The staggering and intense selling knocked a quick 17% off the index ...
Read Full Story »
West side view of the United States Capitol building.

Top Biotechnology Stocks On Sale Again

For the second time in less than a month, the biotechnology sector got whacked when once again, chatter coming from the halls of Congress over drug pricing concerns hit the ...
Read Full Story »
Wall St Bull statue

Oppenheimer Top Stocks to Buy as Bull Market Turns Five Years Old

Five years ago, many investors had thrown in the towel. The S&P 500 hit an ominous intraday low of 666 and closed at 676.53. The world was coming to an ...
Read Full Story »
Biotechnology word cloud

UBS Says Buy Top Biotech Stocks in Front of Earnings for Big Upside

Like many firms on Wall Street, the biotechnology team at UBS thinks that most of the top mega-cap and large cap biotech stocks are poised to beat earnings estimates across ...
Read Full Story »
Pills

UBS Has Nine Biotech Buyout and Merger Candidates

After three years of solid outperformance, most firms on Wall Street that we cover remain very positive on biotechnology as a whole. The analysts at UBS are not only bullish ...
Read Full Story »
Monkey evil

Top Analyst Downgrades, Stocks to Sell: Apple, Twitter, First Solar and More

It is the first full trading week of 2014, and investors are trying to decide how to position their portfolios for the year. Wall Street brokerage firms are making their ...
Read Full Story »
biotech

Solid Biotech Stocks With the Best Revenue Growth for 2014

Any time investors look for companies growing sales the most, one area that almost always stands out is the up and coming biotech stocks. After all, sales can grow from ...
Read Full Story »
biotech

UBS Picks Large Cap Biotechnology Stocks to Outperform the Rest of 2013

Even though the equity strategy team at UBS has downgraded U.S. equities to Neutral from Outperform, they remain very positive on large cap biotechnology names. Acknowledging in their recent report ...
Read Full Story »
biotech

Cowen’s Eight Biotech Stocks to Buy That Could Beat Earnings: Alexion, Ariad and More

Biotechnology stocks have had an extremely solid first half of the year. The analysts at Cowen Group point out that expectations are very high and many of the stocks have ...
Read Full Story »
95992888

Ten Top Large Cap Stocks to Buy With the Most Upside Potential

When we screen stocks at the Wall Street firms we cover, we always are anxious to provide our readers with the stocks that the top firms feel have the most ...
Read Full Story »
biotech

Merrill Lynch Top Biotechnology Stocks to Buy for Big Gains

The higher the market climbs, the harder it becomes for investors to find solid stock ideas to add or scale in to their portfolios. With the market currently teetering on ...
Read Full Story »
pills

Deutsche Bank Firm on Biotech Stocks to Buy

Biotech has strongly outperformed the S&P 500 since January of 2011. The NASDAQ Biotechnology Index (NBI) is up 90%, and the AMEX Biotechnology index (BTK) is up 50%, versus the ...
Read Full Story »
Wall St Bull statue

UBS Top Picks for Second Quarter for 25 Percent Gains (ALXN, ACI, C, CIE, DAL, HAL, BLOX, KRA, MNST, NCT, ROST, TIBX, WCRX, WFM)

When we started off 2013, most of the Wall St. firms we follow put out their top stock picks for the year. We covered those various lists so our readers ...
Read Full Story »
biotech

ETF Folly: Biotech ETFs, Nothing but Confusion

24/7 Wall St. has always wondered about the confusing universe of biotech exchange-traded funds (ETFs). Biotech stocks can rise or fall regardless of the market direction, and the sector performed ...
Read Full Story »
Bull and Bear

Top Analyst Upgrades and Downgrades (ACMP, ALXN, ADI, BIDU, BCS, ESRX, GMCR, LOW, MM, NTSP, RDN, SEE, SPLS, HOT, WIN)

These are some of this Wednesday's top analyst upgrades, downgrades and initiations seen from Wall St. research calls. Access Midstream Partners L.P. (NYSE: ACMP) reiterated Outperform but on Focus List ...
Read Full Story »